November 9, 2015
View Full PaperRedefining Blood-Pressure Targets — SPRINT Starts the Marathon
Key Result
Optimal blood-pressure lowering targets remain debated, with observational data showing conflicting evidence between a linear risk reduction down to 115/75 mm Hg versus a J-shaped curve.
PICO
P
Population
Hypertension
I
Intervention / Comparator
Blood-pressure lowering targets
Abstract
Blood pressure is a potent determinant of cardiovascular risk, but the most appropriate targets for blood-pressure lowering have long been debated. Observational studies with a low risk of confounding have shown a linear relationship between blood pressure and cardiovascular risk down to 115/75 mm Hg,1 but some observational studies with a greater potential for confounding, involving persons at increased risk, have suggested a J-shaped curve — that is, below a given blood pressure, risk would increase. When trials of blood-pressure–lowering drugs have shown benefits in patients without hypertension, these effects have often been ascribed to alternative mechanisms. The widespread uncertainty . . .
Cite This Study
Perkovic et al. (Mon,) conducted a editorial in Hypertension. Blood-pressure lowering targets was evaluated. Optimal blood-pressure lowering targets remain debated, with observational data showing conflicting evidence between a linear risk reduction down to 115/75 mm Hg versus a J-shaped curve.